Metabolic and Metabolomic Effects of Metformin in Murine Model of Pulmonary Adenoma Formation

• Published in: Nutrition and cancer 2023, Vol.75 (3), p.1014-1027
• Main Authors: Elton, Andrew C., Cedarstrom, Vannesa, Quraishi, Arman, Wuertz, Beverly, Murray, Kevin, Markowski, Todd W., Seabloom, Donna, Ondrey, Frank G.
• Format: Article
• Language: English
• Subjects: Adenoma; Adenoma - drug therapy; Adenoma - prevention & control; Animal models; Animals; Anticancer properties; Antidiabetics; Benzo(a)pyrene; Cancer; Cell signaling; Diabetes mellitus; Diet; Disease Models, Animal; Epidemiology; Lung Neoplasms - drug therapy; Lung Neoplasms - prevention & control; Lungs; Mass spectrometry; Mass spectroscopy; Metabolism; Metabolites; Metabolomics; Metformin; Metformin - pharmacology; Mice; Nutrient deficiency; Tumors; Weight Gain; Weight reduction
• ISSN: 0163-5581; 1532-7914
• DOI: 10.1080/01635581.2023.2165692

Epidemiologic studies of diabetic patients treated with metformin identified significantly lower incidences of cancer. From this, there is growing interest in the use of metformin to treat and prevent cancer. Studies have investigated chemopreventive mechanisms including alterations in calorie intake, cancer metabolism, and cell signaling. Repurposing the drug is challenging due to its metabolic effects and non-uniform effects on different types of cancer. In our previously published studies, we observed that benzo[a]pyrene treated mice receiving metformin significantly reduced lung adenomas; however, mice had reduced weight gain. In this study, we compared chemoprevention diets with and without metformin to evaluate the effects of diet vs. effects of metformin. We also performed tandem mass spectrometry on mouse serum to assess metabolomic alterations associated with metformin treatment. In metformin cohorts, the rate of weight gain was reduced, but weights did not vary between diets. There was no weight difference between diets without metformin. Interestingly, caloric intake was increased in metformin treated mice. Metabolomic analysis revealed metabolite alterations consistent with metformin treatment. Based on these results, we conclude that previous reductions in lung adenomas may have been occurred from anticancer effects of metformin rather than a potentially toxic effect such as calorie restriction.